INTERVIEW: IntellaEquity $IEQ.ca Discusses Opportunistic Investments in the Industrial, AI and Blockchain Sectors
FanLogic Interactive $FNLG.ca Launches “CEO Verified†Discussion Forum On AGORACOM To Act As Primary Investor Social Media Platform
- FanLogic is a platform that allows athletes, actors and social media celebrities to better monetize their audiences by converting them from simple followers to active, engaged fans.
- Fanlogic platform provides influencers with smart and engaging tools such as VIP access, contests and loyalty programs that incentivize fans to pay, participate and proliferate in a clean, bully free environment
CALGARY, AB /Â November 2, 2018 / FanLogic Interactive (TSX-V: FLGC – OTCQB: FNNGF) (“FanLogic Interactive” or the “Company”) is pleased to announced the launch of a “CEO Verified” Discussion Forum on AGORACOM. The forum will serve as the Company’s primary social media platform to interact with both shareholders and the broader investment community in a fully moderated environment.
The Company will also receive significant exposure through millions of content brand insertions on the AGORACOM network and extensive search engine marketing over the next 12 months. In addition, exclusive sponsorships of invaluable digital properties such as AGORACOM TV, the AGORACOM home page and the AGORACOM Twitter account will serve to significantly raise the brand awareness of the Company among small cap investors.
MODERATED DISCUSSION FOR PUBLIC COMPANY EXECUTIVES AND SHAREHOLDERS
AGORACOM “CEO Verified” provides the first ever identity verification of small cap executives on a finance platform. For the first time ever, small cap CEO’s and other company officers can post or communicate within a discussion forum without the risk of impersonation leading to catastrophic consequences. As the ultimate influencers of their own companies, “CEO Verified” Forums will create incredible levels of engagement between companies and investors that have long desired civilized, constructive and factual conversation, with no limitations as to the number of characters.
Posts to AGORACOM are shareable on Twitter, Facebook and LinkedIn, which enables the Company to continue utilizing these channels while making AGORACOM the primary HUB of investor engagement.
There are no log-in requirements for investors to visit the forum and read posts. Those wishing to post questions, comments and interact with company officers can quickly log-in using their Facebook or LinkedIn accounts, or create an anonymous new user account.
The FanLogic Discussion Forum can be found at:
https://agoracom.com/ir/FanLogicInteractiveInc
Verified officer at launch:
Randolph H. Brownell III, Chief Executive Officer
Randolph stated, “Social media participation is very important for growth companies such as ours and AGORACOM forums are purpose built to facilitate intelligent discussion without the nonsense that plagues other such sites. I encourage everyone to read and participate in our CEO Verified Discussion Forum to create great, vibrant and constructive discussion for the long term benefit of everyone. “George Tsiolis, AGORACOM Founder stated “This is a service that is long overdue for small cap companies, executives and long-term shareholders that have had no choice but to watch their company message get hijacked on unmonitored forums by unscrupulous investors. CEO Verified Discussion Forums is the killer solution and it is free, so every small cap CEO in North America should be using it and every small cap shareholder should be demanding it.”
SHARES FOR SERVICES
Term and Compensation
TERM: October 22, 2018 – October 31, 2019
FEES: $CDN 50,000 + HST *
- $50,000 + HST to be paid via Shares For Services Under TSX Venture Policy 4.3 (Section 5)
- $10,000 + HST Shares For Services upon Commencement October 22, 2018 for initial set up of HUB, marketing materials and search engine programs.
- $10,000 + HST Shares For Services at end of Third Month January 22, 2018
- $10,000 + HST Shares For Services at end of Sixth Month April 22, 2019
- $10,000 + HST Shares For Services at end of Ninth Month July 22, 2019
- $10,000 + HST Shares For Services at end of Twelfth Month October 31, 2019
Per TSX Venture Policy 4.3 (Section 6.1), the deemed price of the securities to be issued will be determined after the date services are provided to advertiser in each period.
Share issuances to AGORA under this Shares For Services Agreement should be effected pursuant to the “consultant exemption” contained in Section 2.24 of National Instrument 45-106 Prospectus Exemptions. To qualify as a consultant with this exemption, the consultant must be engaged to provide services to the issuer, pursuant to a written contract, other than services provided in relation to a distribution and must spend a significant amount of time and attention on the affairs and business of the issuer.
About FanLogic:
FanLogic is a platform that allows athletes, actors and social media celebrities to better monetize their audiences by converting them from simple followers to active, engaged fans. Our platform provides influencers with smart and engaging tools such as VIP access, contests and loyalty programs that incentivize fans to pay, participate and proliferate in a clean, bully free environment. As a result, influencers are able to optimize their audience and build a massive, engaged fan base for the long term.
For more information about either: FanLogicInteractive.com / FanLogicConnect.com / FanLogic.email, visit the web sites or contact Randy Brownell, CEO, [email protected] or 888-330-0759.FanLogic is a publicly listed company (FLGC:TSXV) (FNNGF:OTCQB) that has also managed branding campaigns for Fortune 500 companies, major sports teams and entertainment companies.
About AGORACOM
AGORACOM is the pioneer of online marketing, broadcasting, conferences and investor relations services to North American small and mid-cap public companies, with more than 300 companies served. AGORACOM is the home of more than 767K investors that visited 5.2 million times and read 53 million pages of information every year. The average duration of visit of 8min 43sec is more than double that of global financial sites, which can be attributed to the implementation and enforcement of the strongest moderation rules in the industry (All Metrics Average 2008 – 2017).
AGORACOM traffic ranks within the top 0.5% of all websites around the world. These traffic results are independently tracked and verified by Google analytics. AGORACOM traffic can be attributed to its strategy of maintaining the cleanest, moderated small-cap discussion, as well as, implementation of the first ever Investor Controlled Stock Discussion Forums in 2007. 10 years later, in 2017, AGORACOM launched the first ever “CEO Verified” Discussion Forums to allow Small Cap CEO’s and Company officers to post comments in a fully verified, moderated and social media shareable environment.
For further information, please contact:
AGORACOM
WEB www.agoracom.com
EMAIL [email protected]
Reader Advisory
Certain information set forth in this news release contains forward-looking statements or information (“forward-looking statements”), including details about the business of the Company and the use of proceeds from the Offering. By their nature, forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond the Company’s control, including the impact of general economic conditions, industry conditions, volatility of commodity prices, currency fluctuations, environmental risks, operational risks, competition from other industry participants, stock market volatility, and the ability to access sufficient capital from internal and external sources. Although the Company believes that the expectations in its forward-looking statements are reasonable, its forward-looking statements have been based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. Risks, uncertainties, material assumptions and other factors that could affect actual results are discussed in our public disclosure documents available at www.sedar.com.
Furthermore, the forward-looking statements contained in this document are made as of the date of this document and, except as required by applicable law, the Company does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE: FanLogic Interactive
$LAB.ca Labrador Gold Announces New Gold Anomalies at its Hopedale Project $WHM.ca $SIC.ca
- Detailed gold exploration results from the Florence Lake Greenstone Belt (FLGB)
- Florence Lake Greenstone Belt is a 57 kilometre strike length of stratigraphy prospective for gold
- Analyses received to date, primarily on two of the larger grids, Misery and Jasmine-Shirley, show significant gold anomalies
- Gold in soil samples from the 5.7km by 2km grid covering the Misery carbonate alteration zone indicate four distinct soil anomalies.
VANCOUVER, British Columbia, Nov. 02, 2018 (GLOBE NEWSWIRE) — Labrador Gold Corp. (TSX-V:LAB) (“Labrador Gold†or the “Companyâ€) is pleased to announce initial results from the first phase of detailed gold exploration in the Florence Lake greenstone belt (FLGB). The company controls a 57 kilometre strike length of stratigraphy prospective for gold in the belt. The exploration program at Florence Lake followed up on successful results of 2017 and included detailed soil sampling, geological mapping, rock sampling and prospecting along the length of the belt.
A total of 11,213 soil samples were taken on 12 grids at a 100m line spacing and 25m sample spacing across the FLGB. Results of 5,511 analyses received to date, primarily on two of the larger grids, Misery and Jasmine-Shirley, show significant gold anomalies typically associated with geological contacts. Analyses range from below detection limit, <0.25 parts per billion (ppb) to 2.22g/t Au, with 19 samples containing more than 0.1g/t Au. In addition, 551 samples greater than the 90th percentile are considered anomalous and require detailed follow up.
Gold in soil samples from the 5.7km by 2km grid covering the Misery carbonate alteration zone indicate four distinct soil anomalies with the two largest measuring 1,300m by 150 m and 750m by 100m, with nine samples containing more than 0.1g/t Au and ranging from 0.1 to 2.1g/t Au in the soil. Anomalies occur at the contact with ultramafic rock and felsic/mafic volcanic rocks and at the contact between ultramafic rocks and felsic intrusive rocks, both common sites of gold mineralization in greenstone belts.
Similarly, gold anomalies over the 2.6km by 0.6km Jasmine-Shirley soil grid occur along the contact between ultramafic rocks and sedimentary rocks (800m by 120m) and in a fold nose in the ultramafic rocks (400m by 250m) with values up to 0.36g/t Au in the soil. The Jasmine-Shirley grid also shows a strong arsenic soil anomaly associated with massive arsenopyrite mineralization with an along strike trend over 1km and highlights of between 0.1 and 1% As in the soil (see figures at www.labradorgold.com/Hopedale).
‘Results received for Misery and Jasmine-Shirley show specific gold targets, typical of greenstone hosted gold mineralization elsewhere in the world, defined by the detailed soil sampling on both grids, said Roger Moss, President and Chief Executive Officer of Labrador Gold. “Soil sampling is working to focus us on the highest potential mineralized areas of the belt and we will follow up these anomalies with detailed mapping, rock sampling and drilling during the next field season.â€
“This summer’s program did exactly what we wanted it to do, identify and pin down the anomalous gold trend on a 25m scale,†added Shawn Ryan, Technical Advisor to Labrador Gold. “The intensity and strength of the targets, both in terms of size of the Misery anomaly and its location right along the contact of the felsic / ultramafic unit, indicates that we truly have a new mineralized system. Three other targets in the area all seem to be following the same pattern with anomalous gold seen along the contacts of either the felsic or mafic units with ultramafic rocks. These areas will be the focus of detailed mapping next season to identify high quality drill targets.â€
All samples were dried in the field before being shipped to the Bureau Veritas preparation laboratory in Timmins, Ontario, with analyses completed at the Vancouver laboratory. Samples were analyzed for gold and another 36 elements by ICP-MS (inductively coupled plasma-mass spectrometry) following an aqua regia digestion. The company routinely submits blanks, field duplicates and certified reference standards with batches of samples to monitor the quality of the analyses.
Roger Moss, PhD., P.Geo., is the qualified person responsible for all technical information in this release.
The company gratefully acknowledges the Newfoundland and Labrador Ministry of Natural Resources’ Junior Exploration Assistance (JEA) Program for its financial support for exploration of the Hopedale property.
About Labrador Gold:
Labrador Gold is a Canadian based mineral exploration company focused on the acquisition and exploration of prospective gold projects in the Americas. In 2017 Labrador Gold signed a Letter of Intent under which the Company has the option to acquire 100% of the 896 square kilometre (km2) Ashuanipi property in northwest Labrador and the Hopedale (458 km2) property in eastern Labrador.
The Hopedale property covers much of the Hunt River and Florence Lake greenstone belts that stretch over 80 km. The belts are typical of greenstone belts around the world but have been underexplored by comparison. Initial work by Labrador Gold during 2017 show gold anomalies in soils and lake sediments over a 3 kilometre section of the northern portion of the Florence Lake greenstone belt in the vicinity of the known Thurber Dog gold showing where grab samples assayed up to 7.8g/t gold. In addition, anomalous gold in soil and lake sediment samples occur over approximately 40 kilometres along the southern section of the greenstone belt (see news release dated January 25th 2018 for more details). Labrador Gold now controls approximately 57km strike length of the Florence Lake Greenstone Belt.
The Ashuanipi gold project is located just 35 km from the historical iron ore mining community of Schefferville, which is linked by rail to the port of Sept Iles, Quebec in the south. The claim blocks cover large lake sediment gold anomalies that, with the exception of local prospecting, have not seen a systematic modern day exploration program. Results of the 2017 reconnaissance exploration program following up the lake sediment anomalies show gold anomalies in soils and lake sediments over a 15 kilometre long by 2 to 6 kilometre wide north-south trend and over a 14 kilometre long by 2 to 4 kilometre wide east-west trend. The anomalies appear to be broadly associated with magnetic highs and do not show any correlation with specific rock types on a regional scale (see news release dated January 18th 2018). This suggests a possible structural control on the localization of the gold anomalies. Historical work 30 km north on the Quebec side led to gold intersections of up to 2.23 grams per tonne (g/t) Au over 19.55 metres (not true width) (Source: IOS Services Geoscientifiques, 2012, Exploration and geological reconnaissance work in the Goodwood River Area, Sheffor Project, Summer Field Season 2011). Gold in both areas appears to be associated with similar rock types.
The Company has 51,592,552 common shares issued and outstanding and trades on the TSX Venture Exchange under the symbol LAB.
For more information please contact:
Roger Moss, President and CEOÂ Â Â Â Â Tel: 416-704-8291
VIDEO: Good Life Networks $GOOD.ca CEO Jesse Dylan Discusses Recent Agreement with AMPD (Game Technology) CEO Anthony Brown $ATVI $TTWO $GAME $EPY.ca $TCEHF $Game.ca $EPY.ca
Bougainville $BOG.ca Signs Binding LOI to Acquire Assets of Gene Bank Research Inc. $CROP.ca $VP.ca NF.ca $MCOA
- Entering the Canadian cannabis market through the signing of a binding Letter of Intent to acquire the assets and inventory of Gene Bank Research Inc.,
- Places Bougainville in a strong position to capitalize on the market opportunities created by the new Cannabis Act.
VANCOUVER, British Columbia, Nov. 01, 2018 — BOUGAINVILLE VENTURES INC. (“Bougainville” or the “Company“) (CSE:BOG) is pleased to announce that it has entered the Canadian cannabis market through the signing of a binding Letter of Intent to acquire the assets and inventory of Gene Bank Research Inc., placing Bougainville in a strong position to capitalize on the market opportunities created by the new Cannabis Act.
About Gene Bank Research Inc.
Gene Bank has over 110 lab-tested craft strains developed by its team of knowledgeable breeders possessing over 17 years’ experience. These unique craft strains allow licensed producers to stand out in an increasingly generic and homogenized market.
The Gene Bank assets include:
- Seeds – a collection of many of the building block genetics of today’s top ranked strains from around the world and used by top breeders
- Clones – the healthiest genetic selections based on specific phenotype/genotype characteristics
- Adult Plants – thousands of plants grown out to select the strongest, healthiest, highest yielding and disease/mold resistance available
- Graphed plants – unique super strains created by graphing the industry’s hardiest strains with weaker more finicky varieties
Principle LOI Terms
- Binding LOI
- Transfer of 100% of Gene Bank’s assets and current inventory to Bougainville
- Payment of $5,000,000 of Bougainville shares, with the price of such BOG shares to be based on 5 day volume weighted average price (“VWAPâ€) by reference to October 30, 2018
- Assets include:
- Seeds
- Genetic Lab Reports
- All Proprietary Information
- Bank Accounts
- Business Deck
- Corporation Documents
CEO, Andy Jagpal Comments:
“The acquisition of Gene Bank greatly expands our reach through vertical integration with the ability to provide unique and highly valued strains of seeds and clones to the cannabis market. I am confident this acquisition can substantially enhance Bougainville’s market value.”
About Bougainville Ventures, Inc.Â
Bougainville provides cannabis infrastructure and seed-to-sale services to I-502 tenant-growers leasing greenhouse facilities space and providing fully built-out, turnkey solutions and ancillary services including processing, cannabis expertise and marketing and sales resources. Greenhouse canopies provide a 50% saving in cultivation cost.
For more information please visit: http://bougainvilleinc.com/
On behalf of the Board of Directors
BOUGAINVILLE VENTURES INC.
Andy Jagpal, CEO and Director
For further information, please contact Andy Jagpal at [email protected] or 1-844-734-8420Â
FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws, including statements regarding the Oroville, WA cultivation facility: statements pertaining to the ability of Bougainville Ventures Inc. (“BOGâ€); the anticipated economic potential of the property; the availability of capital and finance for BOG to execute its strategy going forward. Forward-looking statements are based on estimates and assumptions made by BOG in light of its experience and perception of current and expected future developments, as well as other factors that BOG believes are appropriate in the circumstances. Many factors could cause BOG’s results, performance or achievements to differ materially from those expressed or implied by the forward looking statements, including: discrepancies between actual and estimated results from exploration and development and operating risks, dependence on early exploration stage concessions; uninsurable risks; competition; regulatory restrictions, including environmental regulatory restrictions and liability; currency fluctuations; defective title to mineral claims or property and dependence on key employees. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
No regulatory authority has approved or disapproved the information contained in this news release.
A Social Network You Can Make a Living From #Peeks $PEEK.ca $IDK.ca $BCOV $AVID
Peeks Social has a social network that you can make a living from.
Peeks Social is a live-streaming social network which enables social and commercial interactions, Peer-to-Peer payments, and other social commerce capabilities. Peeks Social is the world’s first social network which bridges the gap between traditional social media and professionally produced content via live or pre-recorded broadcasts. Peeks Social enables content creators to immediately monetize their content through patented and proprietary payment technologies.
The Most Rewarding Live Streaming Platform
Go Live
Start broadcasting your stream from anywhere to anyone in the world.
Get Paid
Collect tips, get sponsored, use paywalls and get paid for your content.
Get Popular
Grow your followers overnight by getting featured in Peeks Social.
Explore
Watch exclusive live streams and videos from around the world and receive special offers.
For more information on Peeks Social Ltd. (PEEK:TSX.V) please fill out the form below.
Source: https://www.b-tv.com/peeks-social-company-feature-ep-332/
Tetra Bio-Pharma $TBP.ca Obtains Health Canada Approval to Conduct a Phase 1 Pharmacokinetic & Safety Study Using Vaporized Version of PPP001 $AERO $CBDS $CGRW $APH.ca $GBLX
- Announced that is has received a “No Objection Letter†(NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version of PPP001.
- This represents the first ever human clinical trial featuring a vaporized cannabinoid drug productÂ
OTTAWA, Nov. 01, 2018 — Tetra Bio-Pharma Inc. (“Tetra†or “TBPâ€) today announced that is has received a “No Objection Letter†(NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version of PPP001.
This study aims to determine the Pharmacokinetic and safety profile of PPP001 delivered as an inhaled vapour using the Mighty Medic (see previous July 16, 2018 News Release), thus providing patients with an alternative to the smoked version of PPP001 and allowing Tetra to develop PPP001 for healthier patients suffering from uncontrolled pain.  It is anticipated that this phase 1 data, combined with Tetra’s characterization of the composition of vapor, will provide the necessary evidence to advance the development of vaporized PPP001 into more chronic and non-life-threatening diseases, such as fibromyalgia. The study is expected to begin and end in Q4 2018.
“We are pleased to announce this critical Phase 1 trial focused on the PK and safety of our PPP001 pellet delivered by vaporization,†said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma Inc. “Over the last 3 months we have analyzed the composition of the vapor. This data combined with the results of this Phase 1 will provide the critical pharmacological information required by physicians to adequately guide future efficacy studies in patients who suffer from a chronic condition such as fibromyalgia where there are limited treatment options and there is a large unmet medical need. It may also provide an alternative mode of delivery for those patients who prefer not to smoke.â€
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
| For further information, please contact Tetra Bio-Pharma Inc. | |
| Robert Bechard | |
| Executive Vice-President Corporate Development and Licensing | |
| 514-817-2514 | |
| [email protected] | |
| Media Contact | |
| energi PR | |
| Carol Levine | Stephanie Engel |
| 514-288-8500 ext. 226 | 416-425-9143 ext. 209 |
| [email protected] | [email protected] |
Tetra $TBP.ca Natural Health Signs Exclusive Agreement for the Distribution of their #Hemp Energy Drink in Canada and the USA $AERO $CBDS $CGRW $APH.ca $GBLX
- Announced that it has signed a major distribution agreement with Kombucha Baby Brewing Company and its partners for the exclusive distribution of its Hemp Energy Drink
- In the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario as well as California, Washington, Oregon and Hawaii.
Tetra Natural Health Looking to Exploit Consumer Appetite for Hemp Based products
OTTAWA, Nov. 01, 2018 – Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (“Tetra†or the “Companyâ€) (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed a major distribution agreement with Kombucha Baby Brewing Company and its partners for the exclusive distribution of its Hemp Energy Drink in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario as well as California, Washington, Oregon and Hawaii.
The Hemp Energy Drink provides consumers with a product that contains fewer calories and more natural ingredients than existing energy drinks thus providing a welcome alternative to existing products in what is considered to be an extremely lucrative market.
“We are thrilled in having signed this agreement with Kombucha Baby and its distribution partners providing Tetra Natural Health with access to a significant number of retail outlets in both Canada and the USA,†stated Richard Giguere, CEO of Tetra Natural Health.
“We are very excited to be adding the Hemp Energy Drink to our portfolio of products that will be available to our existing and potential client base,†stated Dan McKenna, President and CEO of Kombucha Baby Brewing Company Inc. “Numerous Canadian and U.S. customers representing thousands of retail outlets have indicated a strong interest in carrying this unique Natural Health Product (NHP).â€
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of various product launches including the one discussed in this release, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]
Media Contact
energi PR
Carol Levine
514-288-8500 ext. 226
[email protected]
Stephanie Engel
416-425-9143 ext. 209
[email protected]
CLIENT FEATURE: Labrador Gold’s Shaw Ryan Targeting the Under Explored Gold Potential of the Province
-
- Led by Shawn Ryan, who’s prospecting and soil geochemistry work led to the discovery of White Gold, Coffee, and QV projects for a total of 7.5M ounces Au
- White Gold’s geochemical sampling program led to successful drill program
- Exploration has already outlined district scale soil anomalies on two projects in Labrador
- Hopedale property contains the Florence Lake greenstone belt and the Hunt River, both of which are under-explored for gold
- Florence Lake greenstone belt has a 40 KM strike length
- Â Ppreliminary soil geochemical results show arsenic anomalies in several areas
- Arsenic is a pathfinder element when exploring for gold
FULL DISCLOSURE: Labrador Gold is an advertising client of AGORA Internet Relations Corp.
VIDEO: Northbud $NBUD.ca October Construction Update $ACB $WEED.ca $HIP.ca
NORTHBUD October Construction Update. Everything is on schedule!
